Racial Disparities in Breast Cancer Diagnosis and Treatment by Hormone Receptor and HER2 Status

被引:112
|
作者
Chen, Lu [1 ,2 ]
Li, Christopher I. [1 ,2 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA
[2] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
关键词
AFRICAN-AMERICAN WOMEN; HISPANIC WHITE WOMEN; SOCIOECONOMIC-STATUS; RACIAL/ETHNIC DIFFERENCES; SCREENING MAMMOGRAPHY; ETHNIC-DIFFERENCES; INSURANCE STATUS; SURVIVAL; BLACK; STAGE;
D O I
10.1158/1055-9965.EPI-15-0293
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: African American and Hispanic women are more likely to be diagnosed with aggressive forms of breast cancer. Disparities within each subtype of breast cancer have not been well documented. Methods: Using data from 18 SEER cancer registries, we identified 102,064 women aged 20 years or older, diagnosed with invasive breast cancer in 2010-2011, and with known stage, hormone receptor (HR), and HER2 status. Associations between race/ethnicity and cancer stage and receipt of guideline-concordant treatment were evaluated according to HR/HER2 status. Results: Overall, African American and Hispanic women were 30% to 60% more likely to be diagnosed with stage II-IV breast cancer compared with non-Hispanic whites. African American women had 40% to 70% higher risks of stage IV breast cancer across all four subtypes. American Indian/Alaska Native women had a 3.9-fold higher risk of stage IV triple-negative breast cancer. African American and Hispanic whites were 30% to 40% more likely to receive non-guideline-concordant treatment for breast cancer overall and across subtypes. Conclusions: Women in several racial/ethnic groups are more likely to be diagnosed with more advanced stage breast cancer. African American and American Indian/Alaska Native women in particular had the highest risk of being diagnosed with stage IV triple-negative breast cancer. African American and Hispanic women were also consistently at higher risk of not receiving guideline-concordant treatment across subtypes. Impact: These findings provide important characterization of which subtypes of breast cancer racial/ethnic disparities in stage and treatment persist. (C) 2015 AACR.
引用
收藏
页码:1666 / 1672
页数:7
相关论文
共 50 条
  • [31] Comparison of hormone receptor and HER2 status in resected brain metastases and primary breast cancer.
    Tomasevic, Z.
    Milovanovic, Z.
    Tomasevic, Z. M.
    Skender, M.
    Pupic, G.
    Kovac, Z.
    Grujicic, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Variations at HER2 and hormone receptor status in primary and metastatic sites of breast cancer patients.
    Alhan, Nurcan
    Rahatli, Samed
    Kucukoztas, Nadire
    Yalcin, Selim
    Yagmurdur, Mahmut Can
    Dizdar, Omer
    Atilgan, Alev
    Ozdemir, Handan
    Altundag, Ozden
    Ozyilkan, Ozgur
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Hormone receptor and HER2 status: The only predictive factors of response to neoadjuvant chemotherapy in breast cancer
    Baulies, S.
    Cusido, M.
    Gonzalez-Cao, M.
    Tresserra, F.
    Fargas, F.
    Rodriguez, I.
    Ubeda, B.
    Ara, C.
    Fabregas, R.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2015, 35 (05) : 485 - 489
  • [34] Metastatic Breast Cancer: Can Bone Biopsy Be Used To Evaluate Hormone Receptor and HER2 Status?
    Montezuma, Diana
    Bartosch, Carla
    Cohnbra, Nuno
    Lopes, Paula
    Vieira, Renate
    Fernandes, Elisabete
    Silva, Fernando
    Vieira, Joana
    Sarmento, Teresa
    Fonso, Noemia
    Leal, Conceicao
    Afonso, Mariana
    MODERN PATHOLOGY, 2015, 28 : 57A - 57A
  • [35] Assessment of hormone receptor status and HER2 expression by fine needle aspiration biopsy in breast cancer
    Hussain, M
    Cangiarella, J
    Volm, M
    Harris, MN
    Roses, DF
    Berman, RS
    ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (01) : S54 - S55
  • [36] Surgical Management of Breast Cancer in 2010–2011 SEER Registries by Hormone and HER2 Receptor Status
    Ingrid Lizarraga
    Mary C. Schroeder
    Ronald J. Weigel
    Alexandra Thomas
    Annals of Surgical Oncology, 2015, 22 : 566 - 572
  • [37] Metastatic Breast Cancer: Can Bone Biopsy Be Used To Evaluate Hormone Receptor and HER2 Status?
    Montezuma, Diana
    Bartosch, Carla
    Coimbra, Nuno
    Lopes, Paula
    Vieira, Renato
    Fernandes, Elisabete
    Silva, Fernanda
    Vieira, Joana
    Sarmento, Teresa
    Afonso, Noemia
    Leal, Conceicao
    Afonso, Mariana
    LABORATORY INVESTIGATION, 2015, 95 : 57A - 57A
  • [38] DISCORDANCE OF HORMONE RECEPTOR AND HER2 STATUS BETWEEN PRIMARY AND RECURRENT BREAST CANCER: NEW TREATMENT STRATEGY FOR PREDICTING OUTCOME OF PATIENTS WITH BREAST CANCER
    Shiino, Sho
    Kinoshita, Takayuki
    Taruno, Kanae
    Jimbo, Kenjiro
    Asaga, Souta
    Hojo, Takashi
    Yoshida, Masayuki
    Tsuda, Hitoshi
    BREAST, 2013, 22 : S58 - S58
  • [39] HER2 status adds prognostic, but not tamoxifen treatment predictive, information in hormone receptor positive premenopausal primary breast cancer
    Ryden, L.
    Ferno, M.
    Landberg, G.
    Bendahl, P. O.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S63 - S64
  • [40] HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information
    Lisa Rydén
    Göran Landberg
    Olle Stål
    Bo Nordenskjöld
    Mårten Fernö
    Pär-Ola Bendahl
    Breast Cancer Research and Treatment, 2008, 109 : 351 - 357